Letter by González-Costello et al Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-mediated Amyloidosis: Analysis of the APOLLO Study"

José González-Costello^{1

2}, Carlos Casasnovas^{2

3}, Carles Díez-López¹

Affiliations

¹ Advanced Heart Failure and Heart Transplant Unit, Heart Disease Institute (J.G.-C., C.D.-L.), Bellvitge University Hospital, Bellvitge Biomedical Research Institute, Barcelona, Spain.
² Multidisciplinary Familiar Amyloidosis Unit (J.G.-C., C.C.), Bellvitge University Hospital, Bellvitge Biomedical Research Institute, Barcelona, Spain.
³ Neuromuscular Unit, Neurology Department (C.C.), Bellvitge University Hospital, Bellvitge Biomedical Research Institute, Barcelona, Spain.

Comment

José González-Costello et al. Circulation. 2019.

. 2019 Jul 9;140(2):e90-e91.

doi: 10.1161/CIRCULATIONAHA.119.039645. Epub 2019 Jul 8.

José González-Costello^{1

2}, Carlos Casasnovas^{2

3}, Carles Díez-López¹

¹ Advanced Heart Failure and Heart Transplant Unit, Heart Disease Institute (J.G.-C., C.D.-L.), Bellvitge University Hospital, Bellvitge Biomedical Research Institute, Barcelona, Spain.
² Multidisciplinary Familiar Amyloidosis Unit (J.G.-C., C.C.), Bellvitge University Hospital, Bellvitge Biomedical Research Institute, Barcelona, Spain.
³ Neuromuscular Unit, Neurology Department (C.C.), Bellvitge University Hospital, Bellvitge Biomedical Research Institute, Barcelona, Spain.

No abstract available

Comment in

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Solomon SD, et al. Circulation. 2019 Jan 22;139(4):431-443. doi: 10.1161/CIRCULATIONAHA.118.035831. Circulation. 2019. PMID: 30586695 Clinical Trial.